One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case "for" and "against"

Manuel Montero-Odasso, Zahinoor Ismail, Gill Livingston, Manuel Montero-Odasso, Zahinoor Ismail, Gill Livingston

Abstract

Background: Recently, it has been suggested that up to a third of the dementia cases might be preventable. While prevention is always better than cure, this is particularly important in the field of dementia, as current interventions are not able to modify the disease. This article revises the evidence "for" and "against" dementia primary prevention.

Discussion: Evidence "for" is sustained by the Lancet Commission on Dementia Prevention, Intervention and Care that noted a reduction of age-related incidence of dementia in high-income countries. Based on results from large cohort studies and using population attributable risk, the commission concluded that up to 35% of dementia cases could be prevented by modifying nine risk factors: low education, midlife hearing loss, obesity, hypertension, late-life depression, smoking, physical inactivity, diabetes, and social isolation. In this life course conceptual framework, modifications of risk factors can influence dementia decades before clinical disease onset. However, evidence "against" is supported by large randomized controlled trials (RCT, > 250 participants per arm, minimum of 6 months follow-up), primarily set to prevent dementia using lifestyle interventions that have shown modest or negative results. The 2017 National Academy of Medicine report concluded that the current evidence is limited and there are no specific interventions to warrant a public health recommendation for dementia prevention. Multiple pathological pathways are involved in the development of dementia which are theoretically treatable by managing midlife hearing loss and hypertension, and with physical exercise and education, as suggested by robust observational studies. However, evidence from large clinical trials is not conclusive to support that a third of dementia cases might be prevented. Current initiatives testing the effect of lifestyle interventions in larger clinical trials may help to settle this debate.

Keywords: Debate; Dementia; Lifestyle interventions; Multidomain trials; Prevention.

Conflict of interest statement

Dr Montero-Odasso declares that he is Associate Editor on BMC Geriatrics.

References

    1. International AD . The World Alzheimer Report 2015, The Global Impact of Dementia: an analysis of prevalence, incidence, cost and trends. 2016.
    1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–2734. doi: 10.1016/S0140-6736(17)31363-6.
    1. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048–1056. doi: 10.1016/S1474-4422(12)70228-4.
    1. Alzheimer’s Research UK . Action plan for dementia - no time to lose. 2018.
    1. The L. Dementia in the UK: preparing the NHS for new treatments. Lancet. 2018;391(10127):1237. doi: 10.1016/S0140-6736(18)30709-8.
    1. Howard R, Zubko O, Bradley R, et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2019;77(2):164–74. 10.1001/jamaneurol.2019.3762.
    1. Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer’s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14(8):981–988. doi: 10.1016/j.jalz.2018.03.005.
    1. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–794. doi: 10.1016/S1474-4422(14)70136-X.
    1. National Academies of Sciences Engineering and Medicine (U.S.). Committee on Preventing Dementia and Cognitive Impairment. Leshner AI, Landis S, et al. Preventing cognitive decline and dementia : a way forward. Washington, DC: The National Academies Press; 2017.
    1. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–2263. doi: 10.1016/S0140-6736(15)60461-5.
    1. Vellas B, Carrie I, Gillette-Guyonnet S, et al. MAPT study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prev Alzheimers Dis. 2014;1(1):13–22.
    1. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797–805. doi: 10.1016/S0140-6736(16)30950-3.
    1. Gross AL, Chu N, Anderson L, Glymour MM, Jones RN. Coalition Against Major D. Do people with Alzheimer’s disease improve with repeated testing? Unpacking the role of content and context in retest effects. Age Ageing. 2018;47(6):866–871. doi: 10.1093/ageing/afy136.
    1. Montero-Odasso M, Ismail Z, Camicioli R. Alzheimer disease, biomarkers, and clinical symptoms-quo vadis? JAMA Neurol. 2020. 10.1001/jamaneurol.2019.4959.
    1. Montero-Odasso MM, Sarquis-Adamson Y, Speechley M, et al. Association of dual-task gait with incident dementia in mild cognitive impairment: results from the gait and brain study. JAMA Neurol. 2017;74(7):857–865. doi: 10.1001/jamaneurol.2017.0643.
    1. World Health Organization (WHO) Dementia: a public health priority. Geneva: World Health Organization; 2012.
    1. The World Alzheimer’s Report . The benefits of early diagnosis and intervention. London: Alzheimer’s Disease International; 2011. p. 2011.
    1. Montero-Odasso M, Hachinski V. Preludes to brain failure: executive dysfunction and gait disturbances. Neurol Sci. 2014;35(4):601–604. doi: 10.1007/s10072-013-1613-4.
    1. Abell JG, Kivimaki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J. 2018;39(33):3119–3125. doi: 10.1093/eurheartj/ehy288.
    1. Radd-Vagenas S, Duffy SL, Naismith SL, Brew BJ, Flood VM, Fiatarone Singh MA. Effect of the Mediterranean diet on cognition and brain morphology and function: a systematic review of randomized controlled trials. Am J Clin Nutr. 2018;107(3):389–404. doi: 10.1093/ajcn/nqx070.
    1. World Health Organization (WHO) Risk reduction of cognitive decline and demenita. Geneva: WHO Guidelines; 2019.
    1. Montero-Odasso M, Almeida QJ, Burhan AM, et al. SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double-blind trial to improve gait and cognition in mild cognitive impairment. BMC Geriatr. 2018;18(1):93. Published 2018 Apr 16 10.1186/s12877-018-0782-7.
    1. Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer’s Dement. 2020;1–16. 10.1002/alz.12123.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅